Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACAD
DateTimeSourceHeadlineSymbolCompany
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
01/06/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202407:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:55Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:54Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
30/05/202406:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACADAcadia Pharmaceuticals Inc
18/05/202406:05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
15/05/202423:05Business WireAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
10/05/202406:58Business WireAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNASDAQ:ACADAcadia Pharmaceuticals Inc
09/05/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
09/05/202406:05Business WireAcadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
30/04/202406:16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
25/04/202406:05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202423:04Business WireAcadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202423:04Business WireAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
20/04/202406:05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
18/04/202406:05Business WireAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
03/04/202407:05Business WireAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and DevelopmentNASDAQ:ACADAcadia Pharmaceuticals Inc
02/04/202407:05Business WireAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACAD